Cigarettes with ultralow nicotine levels are now being called the game-changer in the fight against smoking. If you are having trouble in quitting smoking, then, it is for you, that soon the Biden White House is expected to formally propose a plan that will order cigarette nicotine levels to be reduced, reports The Washington Post. For now though, it has been a failure, as these cigarettes, also known as VLN cigarettes that stands for very low nicotine are only available in 5,100 stores in 26 states. This is a very small fraction of the overall market for cigarettes. The company that makes it, 22nd Century, is struggling not because of the low supply, but also from the advocates who have long believed slashing nicotine levels altogether.
Nicotine is a chemical that is produced naturally from tobacco that makes the cigarette and also keeps people hooked. While it is believed that it makes people alert, and get the "hit" to keep them going, it exposes the users to harmful substances, carcinogens, and increases the risk of heart disease, lung cancer, and other illness.
Ultralow-nicotine cigarettes, like the VLN brand, contain about 95% less nicotine than the regular cigarettes. The idea is quite simple: without the addictive grip of nicotine, smokers will find it easier to quit. Research too has shown some promise. For instance, the studies funded by the National Institute on Drug Abuse revealed that very low nicotine cigarettes reduced addiction potential significantly without having users to increase their smoking frequency. However, the problem is, why would anyone choose for a low-nicotine that does not make them feel the same way, when the high-nicotine cigarette is right next to it, making them feel the same way, with the same alertness, sold at the same price.
“It’s very hard to imagine someone actively choosing to continue to use a low-nicotine product for the same price when a high-nicotine product is right next to it,” said Eric Donny, a Wake Forest University School of Medicine nicotine researcher.
No wonder, the experiment with low nicotine product by Philip Morris' Next cigarettes in the 1980s and Vector Tobacco's Quest brand in the early 2000s, flopped.
The Food and Drug Administration (FDA) has supported the development of such products, even allowing VLN cigarettes to be marketed as lower-risk options. However, these products remain a niche market, available in only a fraction of U.S. stores.
Recently, the Biden administration has considered a bold step—mandating a dramatic reduction in nicotine levels for all cigarettes sold in the United States. Supporters believe this move could save millions of lives, while critics, including tobacco companies, warn of potential unintended consequences.
Resistance from Big Tobacco Companies: They could argue that slashing nicotine levels could backfire. Their claim is, smokers will turn to black markets or smoke more to satisfy their cravings, which may lead to greater exposure to harmful substances.
Consumer Reluctance: History is proof to the instances of smokers being hesitant to embrace the low-nicotine products.
Political Hurdle: It may face political roadblocks, as under the Trump administration, plans to cut nicotine were shelved.
Advocates believe that ultralow-nicotine cigarettes could be a game-changer, comparing them to decaf coffee or non-alcoholic beer—products that reduce harm while offering a similar experience.
Some experts warn that a black market for traditional cigarettes could undermine these efforts. They also stress the need for safer alternatives, such as vaping products, to support smokers transitioning away from traditional cigarettes.
Credit: AI-generated image
Breckenridge Pharmaceutical, Inc. has announced a voluntary nationwide recall of a batch of Propranolol Hydrochloride Extended-Release Capsules, USP 60 mg in the US over concerns that the medication may contain metal particles.
The recall, announced on November 16, 2026, covers one lot of the blood pressure medication manufactured by Adare Pharma Solutions. The company initiated the recall after identifying a possible contamination linked to an intermediate material used in the affected batch.
According to the company's recall notice, the contaminated material was suspected to be the source of metal contamination identified in a separate lot that was not released into the market.
The company has warned that taking capsules from the affected lot could cause physical injuries to soft tissues in the body.
According to the recall notice, use of the affected product could cause "lacerations of soft tissues in the oral cavity, esophagus, stomach, or intestine."
However, Breckenridge Pharmaceutical stated that it was not aware of any adverse events related to the recall at the time of the announcement.
The affected products were distributed to wholesalers and pharmacies across the US between October 26 and November 4, 2026.
Also read: From 4 To 100 Kratom Capsules A Day: Woman Shares Warning Signs Of Addiction
The recall is limited to a specific batch of 60 mg Propranolol Hydrochloride Extended-Release Capsules. The details are:
Those who have been prescribed the pill between the dates mentioned above are advised to check the product packaging and lot number to determine whether their medication is part of the recall.
Also read: Popular Anti-Anxiety Capsules Recalled Over Salmonella Fears: What Should Patients Know
Breckenridge Pharmaceutical has advised consumers to immediately stop taking the medication from the affected lot and contact their physician or healthcare provider for medical advice for obtaining a replacement.
"Consumers should return any unused portion of the affected product to the pharmacy where it was obtained," the company's announcement said.
Patients should also return any unused capsules from the recalled batch to the pharmacy where they purchased the medication. Anyone who has experienced health problems that could be due to the recalled medicine should contact their healthcare provider.
Pharmacies, wholesalers and other retailers have been instructed to check their inventories, quarantine the affected products and stop distributing or dispensing them.
Consumers seeking additional information about the recall can contact Qualanex, the company's designated recall service provider, at 1-855-736-0807 or email recall@qualanex.com. The recall is being conducted with the knowledge of the US Food and Drug Administration (FDA).
Also read: US FDA Recalls Thousands Of Blood Pressure Drugs Over Excess Drug Levels, Failed Quality Tests
Propranolol belongs to a class of medicines called beta-blockers. It works by reducing the effects of certain stress hormones on the heart, thereby slowing the heart rate and reducing blood pressure.
The medication is commonly prescribed to manage high blood pressure and other cardiovascular conditions. It is also used for certain heart rhythm disorders, angina and migraine prevention.
The extended-release formulation is designed to release the medicine gradually over time, allowing effects that last long.
Propranolol's recall is the latest in a series of recent blood pressure medication recalls, including a recent one involving Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide tablets. They were recalled as they did not dissolve properly. A while go, Chlorthalidone tablets were also recalled for the same reason.
Credit: iStock
Could chewing gum one day help fight cancer? Researchers at the University of Pennsylvania in the US have developed an experimental gum made from lablab beans, also known as Indian beans, that targets human papillomavirus (HPV) and harmful oral bacteria associated with head and neck cancer.
In laboratory tests using oral samples from cancer patients, extracts of the gum reduced HPV levels by up to 93%. An enhanced version also reduced two harmful bacterial species to nearly undetectable levels without affecting the beneficial bacteria tested.
The experimental gum builds on the team's earlier research into lablab beans. It contains FRIL, a naturally occurring plant protein with antiviral properties.
Researchers tested gum extracts against microorganisms in oral samples collected from patients with head and neck cancer.
The results published in Scientific Reports journal showed:
The researchers also developed an enhanced version containing protegrin, an antimicrobial peptide. Peptides are short chains of amino acids, the building blocks of proteins.
A single dose of the enhanced gum extract reduced two targeted bacterial species, Porphyromonas gingivalis (Pg) and Fusobacterium nucleatum (Fn), to nearly undetectable levels.
Also read: HPV Vaccines Can Prevent Head And Neck Cancers In Men, Says Study
The experimental formulation selectively targeted harmful bacteria while leaving the beneficial bacterial populations examined in the study largely unaffected.
The oral microbiome, which consists of microorganisms living inside the mouth, plays an important role in maintaining oral health.
Cancer treatments such as radiation therapy can disrupt this microbial balance, reducing beneficial bacteria and encouraging the growth of potentially harmful microorganisms, including Candida albicans, a type of yeast.
The researchers suggest that selectively targeting harmful microbes while preserving beneficial ones could be particularly useful for patients undergoing cancer treatment.
Read More: Russia's mRNA Cancer Vaccine: First Patient With Melanoma Completes Treatment, Shows No New Tumours
The researchers believe the findings warrant further investigation through human clinical trials. They envision the technology potentially being used alongside existing cancer treatments or as a preventive approach to limit infections.
"Lip and oral cavity cancer was the seventh leading cancer type in cancer incidence and mortality rate worldwide in adolescents, young adults, and middle-aged adults in 2022," Daniell said.
He said the findings support advancing these therapies into clinical trials as additional treatments or as prophylaxis to prevent infection and transmission.
Prophylaxis refers to measures taken to prevent a disease or infection before it occurs.
The plant-based technology could also offer a potentially affordable way to deliver protective proteins directly into the mouth.
However, the findings should be interpreted cautiously. The researchers tested gum extracts on patient samples under laboratory conditions. They have not established whether chewing the gum produces the same results in people or whether reducing these microorganisms can prevent cancer or improve treatment outcomes.
Human clinical trials will be needed to establish its safety and effectiveness. For now, the bean-based gum remains experimental and is not a proven cancer-prevention or treatment option.
Credit: iStock
With one in six laboratory-confirmed bacterial infections worldwide already resistant to antibiotics, drug-resistant infections could contribute to more than 39 million deaths by 2050 if current trends persist, according to the World Health Organization (WHO).
Speaking at the virtual 6th Annual Global Media Forum on AMR, WHO officials warned that countries are not doing enough to tackle antimicrobial resistance (AMR), despite growing commitments. They also presented findings from the latest joint survey by WHO, the United Nations Environment Programme, the World Organisation for Animal Health and the Food and Agriculture Organization.
Although more countries have adopted national action plans to combat AMR, most have failed to translate these commitments into funded and implemented programmes. As a result, the world remains off track to meet key 2030 targets.
Of the 183 countries surveyed, 173 reported having a national action plan, up from 79 in 2017. However, only 42 said their plans were financed and implemented.
Also read: Over One In Four Americans Lied To Get Antibiotics For Children: Why It Can Be Dangerous
Antimicrobial resistance occurs when bacteria, viruses, fungi and parasites evolve and no longer respond to medicines designed to treat them. This makes infections harder to treat and increases the risk of disease spread, severe illness and death.
Antibiotic resistance is a form of AMR that specifically involves bacteria becoming resistant to antibiotics. Misuse and overuse of these medicines accelerate the problem.
At the 2024 United Nations General Assembly, countries agreed on a series of targets to tackle AMR by 2030. However, experts warn that the growing threat could undermine decades of medical progress.
"Procedures we now take for granted become far riskier when antibiotics and antimicrobials no longer work," Jean-Pierre Nyemazi, acting director of WHO's AMR department, said. The development of new antibiotics is also failing to keep pace with the spread of resistance, he added, Reuters reported.
"Unlike COVID-19, which was very visible, drug-resistant infections have been taking people's lives for years without us noticing it and raising the alarm as we should," Nyemazi said at the forum.
In 2021 alone, AMR was directly responsible for more than one million deaths and associated with approximately 4.7 million others, according to WHO figures.
The 2026 survey highlighted major gaps in infection prevention, a key measure for reducing the need for antibiotics.
The WHO reported that 128 countries now have national infection prevention and control programmes and guidelines, up from 90 in 2018. However, only 69 countries, or 38%, have implemented these programmes nationwide, well below the 2030 target of 90%.
Read More: 98 Years After Penicillin: Are We Running Out Of Effective Antibiotics?
Laboratory capacity also remains limited. While 131 countries reported having national reference laboratories capable of testing antibiotic resistance in common bacteria, only 66 could test for both bacterial and fungal resistance. Countries have agreed to ensure that 80% have these capabilities by 2030.
The WHO also released two toolkits to help countries strengthen diagnostic capacity, covering essential tests and laboratory procedures.
Surveillance has improved, with 113 countries now monitoring antibiotic use and 109 tracking antimicrobial resistance, compared with 65 and 39, respectively, in 2017.
However, only 21 countries reported integrating data on antibiotic use and resistance. The WHO said combining these datasets is essential to understand how antibiotic consumption drives resistance and to guide efforts to contain it.
Antibiotics treat bacterial infections but do not work against viral infections, which commonly cause cold- and flu-like symptoms. Unnecessary use can also expose patients to side effects and contribute to antimicrobial resistance.
As per the WHO, resistance exists across 22 different antibiotics—the common drugs used to treat everyday illnesses, such as:
When bacteria develop resistance, infections become harder to treat, increasing the risk of complications and limiting available treatment options.
(With inputs from agencies)
© $2026 Times Horizon Private Limited